Phenylketonuria

Overview and Epidemiology

Phenylketonuria (PKU) is an autosomal recessive inborn error of amino acid metabolism caused by mutations in the PAH gene, which encodes the enzyme phenylalanine hydroxylase (PAH), located on chromosome 12q23.2. PAH normally catalyzes the irreversible hydroxylation of the essential amino acid phenylalanine (Phe) to tyrosine, a reaction requiring tetrahydrobiopterin (BH4) as an essential cofactor. When PAH activity is severely reduced or absent, phenylalanine accumulates to toxic concentrations in blood and brain — a condition termed hyperphenylalaninemia. Left untreated, the resulting neurotoxicity causes profound and irreversible intellectual disability. Detected at birth and treated promptly, children with PKU can achieve completely normal cognitive development.

PKU affects approximately 1 in 10,000–1 in 15,000 newborns in populations of predominantly Caucasian ancestry. Prevalence varies substantially by ethnicity and geography: Ireland has one of the highest rates (~1 in 4,500), Turkey ~1 in 4,000–1 in 6,000, and parts of Eastern Europe are also heavily affected. Conversely, prevalence is considerably lower in African and East Asian populations. More than 600 disease-causing variants in the PAH gene have been catalogued in ClinVar and the PAHvdb database; missense mutations predominate, but nonsense, frameshift, splice-site, and large deletion variants are all well represented.

The disease was first described in 1934 by Norwegian physician Asbjørn Følling, who detected phenylpyruvic acid — an abnormal metabolite — in the urine of two intellectually disabled siblings. Følling's astute biochemical investigation established the link between a single enzyme defect and a specific clinical syndrome, making PKU one of the founding examples of an inborn error of metabolism. The disease was historically called "Følling disease" in his honor. A watershed moment came in 1963 when Robert Guthrie developed a simple, inexpensive newborn screening test using dried blood spots, enabling early detection and dietary intervention before brain damage occurs — one of public health's most impactful achievements in preventing intellectual disability.

Back to Table of Contents

Genetics and Molecular Basis

The PAH gene spans approximately 90 kilobases on chromosome 12q23.2, comprising 13 exons. More than 600 pathogenic variants have been identified, with missense mutations accounting for the majority. PKU is inherited in an autosomal recessive pattern: an individual must inherit two defective copies of the gene — one from each parent — to develop the disease. Compound heterozygosity (two different pathogenic alleles, one inherited from each parent) is extremely common and accounts for the majority of affected individuals outside of consanguineous populations. Carriers of a single pathogenic allele are typically healthy with normal phenylalanine levels.

A clinically critical concept in PKU genetics is the strong genotype-phenotype correlation determined by residual PAH enzyme activity. Mutations that abolish enzyme activity entirely (PAH activity <1% of normal) produce classic PKU with severely elevated blood Phe. Mutations allowing 1–5% residual activity produce mild PKU. Mutations preserving >5% activity result in mild hyperphenylalaninemia (HPA), the mildest phenotype, where blood Phe is elevated above normal but may not require full dietary treatment. Understanding this correlation guides treatment decisions and prognosis.

Tetrahydrobiopterin (BH4) is the essential cofactor for PAH catalysis. BH4 deficiency — caused by mutations in genes encoding enzymes of BH4 synthesis (GCH1, PTS, SPR) or regeneration (QDPR encoding dihydropteridine reductase) — produces a distinct and clinically more complex form of hyperphenylalaninemia requiring additional treatment beyond dietary Phe restriction. These BH4 synthesis or recycling defects must be excluded in every patient with confirmed HPA, as they require treatment with neurotransmitter precursors (L-DOPA, 5-hydroxytryptophan) in addition to BH4 itself, and their neurological deterioration can be severe even with normal Phe levels. Urine pterin profiling and DHPR enzyme assay are the diagnostic tests of choice.

BH4-responsive PKU, distinct from BH4 deficiency disorders, occurs in approximately 25–30% of PAH mutation carriers. In these patients, residual PAH enzyme is structurally present but misfolded or kinetically impaired; pharmacological doses of BH4 act as a molecular chaperone — stabilizing the misfolded protein, preventing its premature degradation, and increasing enzyme activity enough to substantially raise dietary Phe tolerance. This form is identified by a standardized BH4 loading test and underlies the rationale for sapropterin pharmacotherapy.

Back to Table of Contents

Pathophysiology: From Enzyme Deficiency to Neurotoxicity

When PAH activity is severely reduced, dietary phenylalanine cannot be converted to tyrosine at sufficient rates, and plasma Phe rises to toxic levels. The central mechanism of brain injury in PKU involves phenylalanine's competition with other large neutral amino acids (LNAAs) — including tyrosine, tryptophan, leucine, isoleucine, valine, and methionine — for transport across the blood-brain barrier via the LAT1 (large neutral amino acid transporter 1, encoded by SLC7A5). In the context of hyperphenylalaninemia, phenylalanine saturates LAT1, dramatically reducing the brain uptake of all other LNAAs. This has cascading consequences for neurotransmitter synthesis: reduced tyrosine availability impairs dopamine (via DOPA) and norepinephrine production, while reduced tryptophan availability impairs serotonin synthesis (via 5-hydroxytryptophan).

The neurotoxic consequences extend beyond neurotransmitter deficiency. Adequate LNAA supply is essential for protein synthesis during the critical period of rapid postnatal brain growth — synaptic formation, axonal elaboration, and myelination all depend on continuous amino acid availability. Reduced LNAA delivery to the developing brain impairs myelination, a process requiring abundant lipid and protein synthesis in oligodendrocytes, contributing to the white matter abnormalities detectable on brain MRI in insufficiently treated patients. The resulting cognitive impairment is not purely functional (neurotransmitter) but also structural (myelin and synapse formation).

Excess phenylalanine is diverted to alternative metabolic pathways under conditions of PAH deficiency. Transamination of phenylalanine by aminotransferases produces phenylpyruvic acid — the compound Følling detected in 1934 — which is further metabolized to phenylacetic acid and its glutamine conjugate phenylacetylglutamine. These organic acids are excreted in high concentrations in the urine and sweat of untreated PKU patients, producing the characteristic musty or mousy odor that was historically a clinical clue before biochemical testing was available. Phenylethylamine, another minor Phe metabolite, contributes to some of the behavioral symptoms.

Tyrosine becomes a conditionally essential amino acid in PKU because it can no longer be synthesized adequately from phenylalanine. Reduced tyrosine availability decreases melanin synthesis in melanocytes — melanin synthesis requires tyrosine as its precursor — producing the characteristic hypopigmentation of untreated PKU: fair skin, blond hair, and blue eyes even in children from darker-skinned ancestry. This phenotypic feature directly reflects the biochemical block and normalizes partially with adequate tyrosine supplementation. Tyrosine supplementation is incorporated into PKU medical formulas.

Back to Table of Contents

PKU Phenotypes: Classic, Mild, and Hyperphenylalaninemia

Classic PKU represents the most severe end of the phenylketonuria spectrum, defined by PAH enzyme activity below 1% of normal and sustained blood phenylalanine concentrations exceeding 1,200 μmol/L (reference range <120 μmol/L) on an unrestricted diet. Without newborn screening and early dietary intervention, classic PKU reliably causes severe intellectual disability (IQ typically 20–50), seizures, and profound neurological impairment. Classic PKU generally does not respond to BH4 loading — the underlying mutations have abolished enzyme function to a degree that pharmacological BH4 cannot compensate — and requires lifelong low-phenylalanine dietary management, with or without adjunctive pharmacotherapy.

Mild PKU occupies an intermediate position, with PAH activity of 1–5% of normal and blood Phe levels of 600–1,200 μmol/L on a normal diet. Dietary treatment is typically required to prevent neurocognitive consequences, though the degree of restriction may be less severe than in classic PKU. A substantial proportion of mild PKU patients respond to BH4 loading and may be candidates for sapropterin therapy, which can significantly increase their dietary Phe tolerance.

Mild hyperphenylalaninemia (HPA) — sometimes called benign HPA — is characterized by PAH activity above 5% of normal and blood Phe in the range of 120–600 μmol/L on a normal diet, below the threshold for classic PKU. International guidelines vary on whether mild HPA requires dietary treatment; most European guidelines recommend dietary intervention when Phe exceeds 360 μmol/L, while some programs in other countries monitor at lower levels without initiating dietary restriction. Virtually all patients with mild HPA are BH4-responsive and should undergo BH4 loading testing, as sapropterin can often normalize Phe levels entirely without dietary restriction.

BH4-responsive PKU is identified by the BH4 loading test: after a baseline blood Phe measurement, the patient ingests BH4 at 20 mg/kg body weight orally; blood Phe is then measured at 8 and 24 hours. A reduction of Phe by 30% or more from baseline at either time point constitutes a positive response, indicating the presence of residual, pharmacologically stabilizable PAH enzyme. Approximately 25–30% of all PAH mutation carriers are responsive, with the highest rates in mild PKU and mild HPA. Identifying BH4-responsive patients is clinically critical because sapropterin therapy can substantially expand dietary freedom, reducing reliance on Phe-restricted medical formulas and improving quality of life.

Back to Table of Contents

Clinical Features of Untreated PKU

In countries without newborn screening, or historically before the Guthrie test was introduced, PKU presented in infancy and early childhood with a characteristic and devastating neurodevelopmental syndrome. Newborns with PKU appear clinically normal at birth; phenylalanine begins accumulating after feeding is established, and neurological consequences unfold over weeks to months. The window between birth and the onset of irreversible brain damage underscores why newborn screening is so critically important — every day of delay in diagnosis and treatment narrows the margin for a normal outcome.

Intellectual disability is the central and most devastating feature of untreated classic PKU. Without treatment, IQ typically falls in the range of 20–50, representing severe intellectual disability. The disability is progressive in the first years of life as the developing brain is exposed to continuously elevated Phe; after early childhood, the baseline damage is largely fixed. Seizures occur in a majority of untreated patients and include a wide spectrum: infantile spasms, tonic-clonic seizures, absence seizures, and focal seizures. EEG characteristically shows diffuse slowing and epileptiform discharges. Behavioral and psychiatric manifestations are prominent and include hyperactivity, anxiety, depression, aggression, and features overlapping with autism spectrum disorder. These may be present even in treated patients with suboptimal Phe control in later life.

Microcephaly develops progressively as Phe toxicity impairs normal brain growth. Motor abnormalities, including increased muscle tone, tremor, and hyperreflexia, reflect ongoing neurological dysfunction. The characteristic mousy or musty odor of urine and sweat, caused by excretion of phenylacetic acid, was historically a bedside diagnostic clue — an odor so distinctive that experienced clinicians could recognize the diagnosis on entering an untreated patient's room. Hypopigmentation — lighter skin, hair, and eye color relative to family members — results from impaired melanin synthesis and was another historical clinical pointer.

Eczema occurs in a significant proportion of untreated patients, though the precise mechanism linking phenylalanine excess to skin inflammation is not fully established. Brain MRI abnormalities are well-documented and follow a characteristic pattern: T2-hyperintense signal in the periventricular and subcortical white matter, reflecting demyelination or dysmyelination. These changes correlate with metabolic control and can partially reverse with tightening of dietary management, particularly in younger patients — a finding with important implications for long-term monitoring. Children diagnosed and treated from birth by newborn screening programs can achieve entirely normal intellectual development, a testament to the effectiveness of metabolic intervention when started early.

Back to Table of Contents

Maternal PKU Syndrome

Maternal PKU syndrome is among the most urgent challenges in PKU management — a preventable teratogenic catastrophe that occurs when women with PKU carry pregnancies without achieving adequate metabolic control. Phenylalanine crosses the placenta freely and concentrates in the fetal circulation at levels 1.5–2 times maternal levels, because the fetus lacks the PAH capacity to metabolize the transferred Phe. Even when the fetus is merely a heterozygous carrier (not PKU-affected), fetal brain, heart, and somatic development are profoundly damaged by the high intrauterine Phe environment. Phenylalanine acts as a direct teratogen at high concentrations.

The clinical consequences form a specific syndrome. Microcephaly is the most common structural defect, occurring in approximately 73% of pregnancies with uncontrolled maternal Phe. Intellectual disability affects the offspring in over 90% of cases when maternal Phe is uncontrolled throughout pregnancy — striking because the infant may have inherited only one copy of the PAH mutation and would otherwise be a healthy carrier. Congenital heart defects occur in 25–50% of exposed fetuses, including conotruncal defects (tetralogy of Fallot, truncus arteriosus) and septal defects (VSD, ASD). Intrauterine growth restriction (IUGR), low birth weight, and facial dysmorphia complete the syndrome. The risk correlates directly with maternal Phe levels during organogenesis and throughout fetal brain development.

Prevention requires intensive pre-conception counseling and metabolic management. The target maternal blood Phe is below 360 μmol/L ideally throughout pregnancy, with many guidelines recommending 120–240 μmol/L as the optimal range. Crucially, metabolic control must be established before conception — organogenesis begins in the first weeks after fertilization, often before the woman knows she is pregnant. Women with PKU of reproductive age must therefore be supported in maintaining good metabolic control year-round, not only after a positive pregnancy test. Monitoring requires very frequent blood Phe measurements (at least weekly, sometimes more often) and dietitian-supervised formula adjustment throughout the pregnancy. Sapropterin may be used in BH4-responsive women to ease the dietary burden, though its safety in pregnancy continues to be evaluated. Maternal PKU syndrome is entirely preventable with appropriate pre-conception and antenatal management.

Back to Table of Contents

Newborn Screening and Diagnosis

The introduction of newborn screening for PKU transformed the disease from a leading cause of preventable intellectual disability into a manageable chronic condition with a normal prognosis when detected and treated early. The Guthrie test, developed by Robert Guthrie and Ada Susi in 1963, used a bacterial inhibition assay on dried blood spots collected from a heel prick to detect elevated phenylalanine. This simple, inexpensive method, applicable to large populations of newborns, became the template for all subsequent expanded newborn screening programs. Guthrie's innovation is estimated to have prevented intellectual disability in hundreds of thousands of individuals worldwide.

Modern newborn screening programs have replaced the Guthrie bacterial inhibition assay with tandem mass spectrometry (MS/MS), which simultaneously quantifies phenylalanine and hundreds of other metabolites from a single dried blood spot, enabling detection of dozens of metabolic disorders in addition to PKU. MS/MS measures both absolute blood Phe concentration and the Phe:Tyr ratio — a ratio above 2.5 is highly suggestive of PAH deficiency and reduces false-positives from non-specific Phe elevation. Blood is collected at 24–48 hours of life (after feeding is established, to allow Phe accumulation). PKU newborn screening is now universal in all 50 US states, across the European Union, and in most high-income countries globally.

A positive or borderline newborn screen requires prompt confirmatory workup. Plasma quantitative amino acid analysis (fasting) measures Phe and Tyr precisely; Phe above 120 μmol/L on two separate samples confirms hyperphenylalaninemia. The critical next step is exclusion of BH4 deficiency disorders: urine pterins profile (biopterin, neopterin, primapterin) and erythrocyte dihydropteridine reductase (DHPR) enzyme assay are mandatory in every newly diagnosed HPA patient. BH4 deficiency disorders require different treatment (neurotransmitter precursors, BH4 itself) and carry worse neurological prognosis if not identified immediately. Once BH4 deficiency is excluded, PAH gene sequencing confirms the molecular diagnosis, identifies specific mutations, guides genotype-phenotype prediction, enables family carrier testing, and determines BH4-responsiveness likelihood based on known mutation data.

The BH4 loading test (20 mg/kg sapropterin orally; Phe measured at baseline, 8 h, and 24 h) should be performed in all newly diagnosed patients. Long-term monitoring of treated PKU requires regular blood Phe measurements — self-collected dried blood spot cards sent to the laboratory. Target Phe in treated patients: 120–360 μmol/L (most European guidelines); <360 μmol/L (US guidelines). Frequency: weekly in infancy and early childhood, less frequently in stable adults; increases during pregnancy and illness.

Back to Table of Contents

Treatment: Dietary Management and Pharmacotherapy

The cornerstone of PKU management for over 60 years has been a low-phenylalanine diet. Because phenylalanine is an essential amino acid present in all natural proteins, the dietary strategy involves severely restricting or eliminating high-protein natural foods — meat, fish, poultry, eggs, dairy products, legumes, and most grains — which together provide the bulk of dietary Phe. Small, carefully measured amounts of natural protein are permitted, individually titrated to each patient's blood Phe tolerance (which varies by residual PAH activity, age, and growth demands). The bulk of protein, energy, and micronutrients must be supplied by specialized Phe-free amino acid medical formulas, which provide all essential amino acids (with ample tyrosine supplementation), vitamins, and minerals without phenylalanine. These formulas are unpalatable to many patients and adherence, particularly in adolescence and adulthood, is a major clinical challenge.

A critical shift in the field over recent decades has been the recognition that PKU is a lifelong condition requiring lifelong dietary management — not a childhood-only disease that can be relaxed in adulthood. Studies consistently show that adults with PKU who relax dietary control experience cognitive deterioration, executive function impairment, psychiatric symptoms, and measurable white matter changes on brain MRI. Adult PKU management remains challenging; many patients struggle with the demanding restrictions, and transition from pediatric to adult services often leads to metabolic deterioration. Products sweetened with aspartame (NutraSweet, Equal) must be strictly avoided — aspartame is a dipeptide of aspartate and phenylalanine, and its consumption causes a rapid Phe spike in PKU patients; food labeling laws require "PHENYLKETONURICS: CONTAINS PHENYLALANINE" warnings on all aspartame-containing products.

Sapropterin dihydrochloride (Kuvan, BioMarin) is a synthetic form of BH4, approved by the FDA in 2007 for PKU patients who have demonstrated BH4 responsiveness. It is the first pharmacological treatment for PKU. Sapropterin acts as a pharmacological chaperone for the PAH enzyme — it stabilizes the misfolded or kinetically impaired enzyme, preventing its degradation and increasing its residual activity. In responsive patients, treatment allows substantially higher dietary Phe tolerance, often reducing or partially eliminating the need for medical formula and expanding the range of acceptable foods. Dose is 10–20 mg/kg/day orally (tablet or dissoluble formulation). Sapropterin does not benefit patients with classic PKU caused by null or severely dysfunctional PAH alleles — the underlying enzyme must be present, even if misfolded, for chaperone therapy to work.

Pegvaliase (Palynziq, BioMarin) was approved by the FDA in 2018 for adult patients with PKU who have uncontrolled Phe levels on existing management. It represents a fundamentally different mechanism: rather than supporting the endogenous PAH enzyme, pegvaliase is a PEGylated recombinant phenylalanine ammonia lyase (PAL) derived from the cyanobacterium Anabaena variabilis. PAL metabolizes phenylalanine through an alternative pathway to ammonia and trans-cinnamic acid, completely bypassing the dysfunctional PAH enzyme. Administered by subcutaneous injection, pegvaliase achieves dramatically reduced blood Phe — many patients reach near-normal levels (<120 μmol/L) after dose titration. Significant adverse effects include systemic hypersensitivity and immune-mediated reactions (requiring mandatory enrollment in a Risk Evaluation and Mitigation Strategy [REMS] program, pre-treatment antihistamine and analgesic, and a 60-minute post-injection observation period during initiation), arthralgia, fatigue, and injection site reactions. A slow, individualized dose escalation protocol over many months is required.

Large neutral amino acid (LNAA) supplementation provides an alternative strategy for adult PKU patients who cannot adhere to dietary treatment or who are not candidates for other therapies. Supplementing LNAA competes with phenylalanine at the LAT1 transporter on the blood-brain barrier, reducing Phe entry into the brain even without lowering systemic blood Phe levels. While LNAA supplements do not normalize blood Phe, they can reduce brain phenylalanine and alleviate some neurological and psychiatric symptoms. Looking ahead, PAH gene therapy trials using adeno-associated virus (AAV) vectors are in active clinical development. Early-phase results are promising, with sustained reductions in blood Phe following a single AAV administration, potentially offering a durable cure-like approach for classic PKU.

Back to Table of Contents

Key Research Papers

  1. Blau N, et al. Phenylketonuria. Lancet. 2010;376(9750):1417-1427. PMID: 20971365
  2. van Wegberg AMJ, et al. The complete European guidelines on phenylketonuria. Orphanet J Rare Dis. 2017;12(1):162. PMID: 29025426
  3. Vockley J, et al. Phenylalanine hydroxylase deficiency. Genet Med. 2014;16(2):188-200. PMID: 24385074
  4. Blau N. Genetics of Phenylketonuria. Int J Neonatal Screen. 2016;2(2):9. DOI: 10.3390/ijns2020009
  5. Burton BK, et al. A phase 3 trial of sapropterin for phenylketonuria. N Engl J Med. 2007;357(22):2209-2215. PMID: 18046028
  6. Longo N, et al. Single-dose, subcutaneous recombinant phenylalanine ammonia lyase conjugated with polyethylene glycol in adult patients with phenylketonuria. Lancet. 2014;384(9937):37-44. PMID: 24889231
  7. Waisbren SE, et al. Effect of blood phenylalanine levels on cognitive outcomes in adults with phenylketonuria. Neurology. 2007;69(22):2041-2048. PMID: 18040003
  8. Koch R, et al. Maternal phenylketonuria: an international study. Mol Genet Metab. 2003;79 Suppl 1:S97-106. PMID: 12936966
  9. Muntau AC, et al. Tetrahydrobiopterin as an alternative treatment for mild phenylketonuria. N Engl J Med. 2002;347(26):2122-2132. PMID: 12501224
  10. Guthrie R, Susi A. A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics. 1963;32:338-343. PMID: 14063511
  11. Lichter-Konecki U, et al. Phenylketonuria and hyperphenylalaninemia. Adv Exp Med Biol. 2017;959:1-28. PMID: 28755183
  12. Scala I, et al. Long-term outcome in patients with classical phenylketonuria. Eur J Pediatr. 2012;171(9):1299-1306. PMID: 22535260

Connections